IBM Watson for Clinical Trials Matching (CTM) is an artificial intelligence platform that matches patients to clinical trials. CTM evaluated 102 Australian lung cancer patients for agreement with gold standard (clinician consensus). CTM agreement was 77-100% overall with 91.6% accuracy for individual trial eligibility. CTM allows efficient and reliable screening of cancer patients for clinical trials with excellent accuracy in exclusion and good performance in assessing eligibility; however, clinician input and oversight is still required.
Learning Objective: After participating in this panel, the learner should be able to:
Understand challenges with assessing and matching patients with lung cancer, to clinical trials at a Cancer Center in Australia.
Learn about a pilot study implemented with an AI-based tool for clinical trial coordination.
Understand an evaluation approach for an automated clinical trial eligibility tool for patients with lung cancer in Australia
Marliese Alexander, Peter MacCallum Cancer Center
Benjamin Solomon, Peter MacCallum Cancer Center
David Ball, Peter MacCallum Cancer Center
Mimi Sheerin, IBM Watson Health
Irene Dankwa-Mullan, IBM Watson Health
Gretchen Jackson, IBM Watson Health
Dishan Herath (Presenter)
Peter MacCallum Cancer Center